CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...